Zepbound vs Liraglutide: Cost and Access Head-to-Head

Clinical Efficacy: What the Trials Actually Show

Zepbound delivers substantially greater weight reduction than liraglutide across their respective key trials. No head-to-head trial has directly compared these two drugs, so the comparison relies on cross-trial analysis with the usual caveats about differing populations, durations, and placebo responses.

In SURMOUNT-1 (N=2,539), participants receiving tirzepatide 15 mg lost a mean of 20.9% of body weight at 72 weeks, compared with 3.1% in the placebo arm [1]. The 10 mg dose produced 19.5% loss, and even the lowest 5 mg dose achieved 15.0%. These numbers represent the largest weight reductions seen in any GLP-1 class trial at the time of publication.

Liraglutide's landmark SCALE Obesity and Prediabetes trial (N=3,731) showed 8.0% mean body-weight loss at 56 weeks with the 3.0 mg daily dose, versus 2.6% for placebo [2]. That 5.4 percentage-point difference over placebo was considered clinically meaningful when the trial published in 2015. By today's standards, it sits well below tirzepatide's performance.

The gap is real but context matters. SURMOUNT-1 ran 16 weeks longer than SCALE. Baseline BMI differed slightly between the two populations. Placebo-subtracted weight loss was approximately 17.8 percentage points for tirzepatide 15 mg versus 5.4 points for liraglutide 3.0 mg, a roughly 3.3-fold difference in net treatment effect [1][2]. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity ranks tirzepatide among the most effective available agents and places liraglutide in a lower efficacy tier [3].

Mechanism Differences: Why the Efficacy Gap Exists

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Liraglutide targets only GLP-1 receptors. That single mechanistic difference explains much of the efficacy separation.

GLP-1 receptor activation slows gastric emptying, reduces appetite through hypothalamic signaling, and enhances glucose-dependent insulin secretion. These effects are well-characterized and form the pharmacological basis for both drugs [4]. Tirzepatide adds activation of glucose-dependent insulinotropic polypeptide (GIP) receptors, which appear to amplify the metabolic effects beyond what GLP-1 agonism alone achieves. Preclinical data suggest GIP receptor activation contributes to improved lipid metabolism and may enhance central appetite suppression through complementary neural pathways [5].

A single injection of tirzepatide once weekly replaces what liraglutide requires daily. This dosing frequency difference carries practical implications for adherence. Patients on weekly injections show higher persistence rates across GLP-1 class drugs, according to a retrospective claims analysis published in Diabetes, Obesity and Metabolism [6]. For a 72-week treatment course, tirzepatide requires roughly 72 injections. Liraglutide requires approximately 504.

List Price Comparison

Both drugs carry high list prices, but the sticker numbers tell only part of the story. Net costs after rebates, coupons, and insurance vary enormously between patients.

Zepbound launched in late 2023 with a wholesale acquisition cost (WAC) of approximately $1,059.87 per month across all dose strengths [7]. Eli Lilly also introduced the LillyDirect program, offering select doses through its own pharmacy channel at reduced cash-pay prices. As of early 2026, certain Zepbound doses have been available at single-dose vial pricing that undercuts the standard pen price.

Saxenda (liraglutide 3.0 mg for obesity) carries a list price of roughly $1,349 per month for the standard five-pen carton [8]. This is somewhat counterintuitive: the older, less effective drug has a higher list price than Zepbound. The difference partially reflects Novo Nordisk's pricing structure and the fact that Saxenda has not seen the competitive price reductions that newer entrants might force.

A useful framework for patients evaluating true out-of-pocket cost should account for four variables: (1) formulary tier and copay, (2) manufacturer coupon eligibility, (3) deductible status, and (4) annual out-of-pocket maximum. A drug with a lower list price can cost more at the pharmacy counter if it sits on a higher formulary tier or lacks coupon support.

Insurance Coverage: The Real Access Barrier

Insurance coverage diverges sharply between these two medications, and coverage patterns have shifted since 2024.

Commercial insurance plans have increasingly added Zepbound to formularies, though many still require prior authorization with documented BMI ≥ 30 kg/m² (or ≥ 27 with a weight-related comorbidity), failure of lifestyle modification, and sometimes failure of a first-line agent [9]. The American Association of Clinical Endocrinology (AACE) consensus statement on obesity pharmacotherapy supports insurance coverage of FDA-approved anti-obesity medications as medically necessary treatments, not cosmetic interventions [10].

Saxenda has been on the market since 2014, giving it a longer coverage track record. Many commercial plans cover it, though step therapy requirements may mandate trying it before approving Zepbound. This creates a paradox: plans sometimes require patients to use the less effective drug first.

Medicare Part D does not cover anti-obesity medications under current law. This exclusion affects both Zepbound and Saxenda equally. The Treat and Reduce Obesity Act has been reintroduced in Congress multiple times but has not passed as of mid-2026 [11]. For Medicare beneficiaries, the entire cost falls out of pocket unless they qualify under a diabetes indication (Mounjaro for tirzepatide, Victoza for liraglutide at the lower 1.8 mg dose).

State Medicaid coverage varies dramatically. Some state Medicaid programs cover anti-obesity medications; others explicitly exclude them. A Kaiser Family Foundation analysis found that fewer than half of state Medicaid programs covered any GLP-1 receptor agonist for obesity as of 2024 [12].

Generic Liraglutide: Current Status

No generic version of liraglutide 3.0 mg (Saxenda) for obesity is available in the United States as of May 2026. The generic question is more nuanced than it appears.

Liraglutide is a biologic peptide, not a small molecule. This means potential competitors would file as biosimilars under the 351(k) pathway rather than as traditional generics under an ANDA. The FDA's biosimilar approval pathway requires analytical, preclinical, and clinical studies demonstrating biosimilarity, which adds time and expense compared to small-molecule generic development [13].

Novo Nordisk's patents on liraglutide formulations and delivery devices have created a thicket that delays biosimilar entry. Some key patents expired or will expire in the mid-2020s, but device patents and formulation patents extend coverage beyond the core compound patent. International markets may see biosimilar liraglutide sooner than the U.S.

Even when a biosimilar arrives, the price reduction may be modest. Biosimilars for injectable biologics typically launch at 15-30% discounts to the reference product, far less than the 80-90% reductions common with small-molecule generics [14]. A biosimilar liraglutide at a 20% discount to Saxenda's list price would still cost over $1,000 per month before insurance.

Dosing, Titration, and Practical Differences

The day-to-day experience of using these medications differs in ways that affect real-world outcomes beyond what clinical trials measure.

Zepbound uses a prefilled single-dose pen injected once weekly. Titration starts at 2.5 mg weekly for four weeks, then increases to 5 mg. Subsequent increases to 10 mg and 15 mg occur at four-week intervals based on tolerability [7]. The total titration period to the maximum dose spans at least 20 weeks.

Liraglutide requires daily subcutaneous injection from a multi-dose pen. Titration begins at 0.6 mg daily for one week, increasing by 0.6 mg each week until reaching the 3.0 mg maintenance dose at week five [8]. Faster titration to max dose, but daily injection burden.

Gastrointestinal side effects are the most common adverse events for both drugs. In SURMOUNT-1, nausea occurred in 24.6% of patients on tirzepatide 15 mg [1]. In SCALE, nausea affected 40.2% of those on liraglutide 3.0 mg [2]. The higher nausea rate with liraglutide may partly reflect the daily dosing pattern, though direct comparison across trials is imperfect. Vomiting, diarrhea, and constipation followed similar patterns, with both drugs showing dose-dependent GI effects.

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, has noted: "The choice between anti-obesity medications should factor in not just the magnitude of weight loss but also the patient's ability to tolerate and persist with treatment over years, since obesity is a chronic disease requiring long-term management" [15].

Who Should Consider Each Drug

Clinical decision-making between Zepbound and liraglutide depends on several patient-specific factors that go beyond headline efficacy numbers.

Patients with BMI ≥ 40, or those needing to lose more than 20% of body weight for health reasons, will likely benefit more from tirzepatide's greater efficacy ceiling. The SURMOUNT-1 data showed that 36.2% of participants on tirzepatide 15 mg achieved ≥ 25% body-weight loss [1]. No liraglutide trial has shown similar response rates at that threshold.

Liraglutide may still be appropriate for patients who need moderate weight loss (5-10%), whose insurance requires step therapy starting with an older agent, or who prefer a medication with a longer post-marketing safety track record. Saxenda has over a decade of real-world safety data. Zepbound's post-marketing experience, while growing rapidly, spans only since late 2023.

Patients with type 2 diabetes face a different formulary situation. Mounjaro (tirzepatide, same molecule as Zepbound but indicated for diabetes) and Victoza (liraglutide 1.8 mg for diabetes) are covered under diabetes formulary tiers, which typically have better coverage than obesity tiers. A clinician prescribing for a patient with both obesity and diabetes may find the diabetes indication opens access that the obesity indication does not.

The American Diabetes Association's Standards of Care 2025 recommends GLP-1 receptor agonists with proven weight-loss benefit for patients with type 2 diabetes and overweight or obesity, noting tirzepatide's superior glycemic and weight outcomes [16].

Cost-Effectiveness Evidence

Health economic analyses are beginning to quantify whether the added efficacy of tirzepatide justifies any cost premium over liraglutide.

The Institute for Clinical and Economic Review (ICER) published a 2024 assessment of tirzepatide for obesity and estimated a value-based price benchmark substantially below its current list price [17]. ICER's analysis suggested that at list price, tirzepatide exceeded commonly cited willingness-to-pay thresholds. At net price (after rebates), the cost-effectiveness ratio improved but remained above $100,000 per quality-adjusted life year in several scenarios.

Liraglutide's cost-effectiveness has been debated since its 2014 approval. A systematic review in PharmacoEconomics found that liraglutide 3.0 mg was cost-effective at willingness-to-pay thresholds of $100,000-$150,000 per QALY in some models, particularly when downstream cardiovascular and diabetes prevention benefits were included [18]. Without those downstream benefits, cost-effectiveness was less favorable.

Neither drug looks like a bargain at current U.S. pricing. The value proposition depends heavily on how long-term health benefits are modeled and what time horizon the analysis uses. A 10-year horizon that captures prevented diabetes cases and cardiovascular events favors both drugs more than a 1-3 year horizon focused only on weight change.

Switching Between Zepbound and Liraglutide

Patients and clinicians sometimes need to switch between agents due to insurance changes, side effects, or inadequate response.

No published clinical trial has specifically studied switching from tirzepatide to liraglutide or vice versa. In practice, switching from liraglutide to Zepbound is more common, typically motivated by a desire for greater weight loss. The transition does not require a washout period. Most clinicians restart tirzepatide at the 2.5 mg starting dose regardless of prior liraglutide dose to allow GIP receptor adaptation and minimize GI side effects.

Switching from Zepbound to liraglutide is less common but may be necessary if insurance coverage changes. Weight regain during the transition is expected, since liraglutide's lower efficacy ceiling means some of the weight lost on tirzepatide may not be maintainable. The SURMOUNT-4 trial demonstrated that discontinuing tirzepatide led to significant weight regain, and stepping down to a less potent agent could produce a partial version of that effect [19].

Dr. Ania Jastreboff, associate professor at Yale School of Medicine and lead investigator on the SURMOUNT-1 trial, has stated: "Obesity is a chronic, relapsing disease. Changing medications is sometimes necessary, and patients should work with their clinicians to set realistic expectations about what each drug can achieve" [20].

The Compounding Pharmacy Question

Compounded versions of both tirzepatide and liraglutide have been available through compounding pharmacies during periods when the branded products were on the FDA's drug shortage list. This market deserves careful scrutiny.

The FDA updated its guidance on compounding GLP-1 receptor agonists as supply stabilized in 2025, and the agency has taken enforcement actions against compounders making copies of products no longer in shortage [21]. Compounded tirzepatide and liraglutide are not FDA-approved, are not subject to the same manufacturing standards as commercial products, and carry unknown bioequivalence profiles.

Prices for compounded versions have ranged from $150-$500 per month, making them attractive to cash-pay patients. The trade-off is uncertainty about potency, sterility, and stability. Several adverse event reports linked to compounded semaglutide and tirzepatide have been filed with the FDA's MedWatch system [22]. Patients considering compounded alternatives should discuss the risk-benefit calculation with their prescribing clinician.

Bottom Line: Matching the Drug to the Patient

Zepbound wins on efficacy by a wide margin. Liraglutide wins on length of real-world safety data and, in some formulary configurations, easier initial access through step therapy. Neither wins on price. The two most important variables for any individual patient are insurance formulary status (call your plan before assuming coverage) and clinical weight-loss goal. Patients targeting more than 15% body-weight loss should pursue tirzepatide access first, since liraglutide's efficacy ceiling in SCALE was 8.0% mean loss at 56 weeks [2]. Patients whose plans mandate liraglutide as a first step can expect meaningful but more moderate results, with the option to appeal for tirzepatide if the response is insufficient after 16-24 weeks on the maximum 3.0 mg dose.